Antidepressants in Japan
Antidepressants in Japan are a class of medications used primarily to treat depression, but also for other mental health conditions. In Japan, the use of antidepressants has been influenced by cultural, societal, and medical factors unique to the country.
History[edit | edit source]
The history of antidepressants in Japan is marked by a late introduction compared to Western countries. The first antidepressant, iproniazid, was not introduced until 1958, several years after its introduction in the United States. This delay was due to a variety of factors, including societal stigma towards mental health disorders and a lack of understanding about the biological basis of depression.
Usage[edit | edit source]
The usage of antidepressants in Japan has increased significantly over the past few decades. This is due in part to a shift in societal attitudes towards mental health, as well as changes in the Japanese healthcare system that have made it easier for individuals to seek treatment for mental health disorders. Despite this increase, the usage of antidepressants in Japan remains lower than in many Western countries.
Types of Antidepressants[edit | edit source]
There are several types of antidepressants available in Japan, including Selective serotonin reuptake inhibitors (SSRIs), Serotonin and norepinephrine reuptake inhibitors (SNRIs), and Tricyclic antidepressants (TCAs). Each of these types of antidepressants works in a slightly different way to alleviate the symptoms of depression.
Cultural and Societal Factors[edit | edit source]
Cultural and societal factors have played a significant role in the use of antidepressants in Japan. Historically, there has been a strong stigma associated with mental health disorders in Japan, which has made it difficult for individuals to seek treatment. However, this stigma has been gradually decreasing, leading to an increase in the use of antidepressants.
Regulation[edit | edit source]
The regulation of antidepressants in Japan is overseen by the Pharmaceuticals and Medical Devices Agency (PMDA). The PMDA is responsible for ensuring the safety and efficacy of all medications sold in Japan, including antidepressants.
See Also[edit | edit source]
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
